1
|
Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment. J Pers Med 2021; 11:jpm11121329. [PMID: 34945801 PMCID: PMC8706948 DOI: 10.3390/jpm11121329] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 11/10/2021] [Accepted: 12/06/2021] [Indexed: 02/06/2023] Open
Abstract
Age-related macular degeneration (AMD) is an incurable disease associated with aging that destroys sharp and central vision. Increasing evidence implicates both systemic and local inflammation in the pathogenesis of AMD. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is currently the first-line therapy for choroidal neovascularization in AMD patients. However, a high number of patients do not show satisfactory responses to anti-VEGF treatment after three injections. Predictive treatment response models are one of the most powerful tools for personalized medicine. Therefore, the application of these models is very helpful to predict the optimal treatment for an early application on each patient. We analyzed the transcriptome of peripheral blood mononuclear cells (PBMCs) from AMD patients before treatment to identify biomarkers of response to ranibizumab. A classification model comprised of four mRNAs and one miRNA isolated from PBMCs was able to predict the response to ranibizumab with high accuracy (Area Under the Curve of the Receiver Operating Characteristic curve = 0.968), before treatment. We consider that our classification model, based on mRNA and miRNA from PBMCs allows a robust prediction of patients with insufficient response to anti-VEGF treatment. In addition, it could be used in combination with other methods, such as specific baseline characteristics, to identify patients with poor response to anti-VEGF treatment to establish patient-specific treatment plans at the first visit.
Collapse
|
2
|
Stuchi LP, Castanhole-Nunes MMU, Maniezzo-Stuchi N, Biselli-Chicote PM, Henrique T, Padovani Neto JA, de-Santi Neto D, Girol AP, Pavarino EC, Goloni-Bertollo EM. VEGFA and NFE2L2 Gene Expression and Regulation by MicroRNAs in Thyroid Papillary Cancer and Colloid Goiter. Genes (Basel) 2020; 11:genes11090954. [PMID: 32824922 PMCID: PMC7563674 DOI: 10.3390/genes11090954] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 08/06/2020] [Accepted: 08/10/2020] [Indexed: 12/24/2022] Open
Abstract
Deregulation of VEGFA (Vascular Endothelial Growth Factor A) and NFE2L2 (Nuclear Factor (Erythroid-derived 2)-Like 2), involved in angiogenesis and oxidative stress, can lead to thyroid cancer progression. MiR-17-5p and miR-612 are possible regulators of these genes and may promote thyroid disorders. In order to evaluate the involvement of VEGFA, NFE2L2, hsa-miR-17-5p, and hsa-miR-612 in thyroid pathology, we examined tissue samples from colloid goiter, papillary thyroid cancer (PTC), and a normal thyroid. We found higher levels of VEGFA and NFE2L2 transcripts and the VEGFA protein in goiter and PTC samples than in normal tissue. In the goiter, miR-612 and miR-17-5p levels were lower than those in PTC. Tumors, despite showing lower VEGFA mRNA expression, presented higher VEGFA protein levels compared to goiter tissue. In addition, NRF2 (Nuclear Related Transcription Factor 2) protein levels in tumors were higher than those in goiter and normal tissues. Inhibition of miR-17-5p resulted in reduced NFE2L2 expression. Overall, both transcript and protein levels of NFE2L2 and VEGFA were elevated in PTC and colloid goiter. Hsa-miR-612 showed differential expression in PTC and colloid goiter, while hsa-miR-17-5p showed differential expression only in colloid goiter, suggesting that hsa-miR-17-5p may be a positive regulator of NFE2L2 expression in PTC.
Collapse
MESH Headings
- Apoptosis
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Case-Control Studies
- Cell Proliferation
- Female
- Gene Expression Regulation, Neoplastic
- Goiter, Nodular/genetics
- Goiter, Nodular/metabolism
- Goiter, Nodular/pathology
- Humans
- Male
- MicroRNAs/genetics
- Middle Aged
- NF-E2-Related Factor 2/genetics
- NF-E2-Related Factor 2/metabolism
- Prognosis
- Thyroid Cancer, Papillary/genetics
- Thyroid Cancer, Papillary/metabolism
- Thyroid Cancer, Papillary/pathology
- Thyroid Neoplasms/genetics
- Thyroid Neoplasms/metabolism
- Thyroid Neoplasms/pathology
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A/genetics
- Vascular Endothelial Growth Factor A/metabolism
Collapse
Affiliation(s)
- Leonardo P. Stuchi
- Research Unit in Genetics and Molecular Biology—UPGEM, Faculty of Medicine of São José do Rio Preto—FAMERP, São José do Rio Preto 15090-000, Brazil; (L.P.S.); (M.M.U.C.-N.); (P.M.B.-C.); (E.C.P.)
| | - Márcia Maria U. Castanhole-Nunes
- Research Unit in Genetics and Molecular Biology—UPGEM, Faculty of Medicine of São José do Rio Preto—FAMERP, São José do Rio Preto 15090-000, Brazil; (L.P.S.); (M.M.U.C.-N.); (P.M.B.-C.); (E.C.P.)
| | - Nathália Maniezzo-Stuchi
- Padre Albino University Center—UNIFIPA, Catanduva, São Paulo 15809-144, Brazil; (N.M.-S.); (A.P.G.)
| | - Patrícia M. Biselli-Chicote
- Research Unit in Genetics and Molecular Biology—UPGEM, Faculty of Medicine of São José do Rio Preto—FAMERP, São José do Rio Preto 15090-000, Brazil; (L.P.S.); (M.M.U.C.-N.); (P.M.B.-C.); (E.C.P.)
| | - Tiago Henrique
- Laboratory of Molecular Markers and Bioinformatics, Department of Molecular Biology, Faculty of Medicine of São José do Rio Preto —FAMERP, São José do Rio Preto 15090-000, Brazil;
| | - João Armando Padovani Neto
- Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine of São José do Rio Preto —FAMERP, São José do Rio Preto 15090-000, Brazil;
| | - Dalisio de-Santi Neto
- Pathological Anatomy Service, Hospital de Base, Foundation Regional Faculty of Medicine of São José do Rio Preto—FUNFARME, São José do Rio Preto 15090-000, Brazil;
| | - Ana Paula Girol
- Padre Albino University Center—UNIFIPA, Catanduva, São Paulo 15809-144, Brazil; (N.M.-S.); (A.P.G.)
| | - Erika C. Pavarino
- Research Unit in Genetics and Molecular Biology—UPGEM, Faculty of Medicine of São José do Rio Preto—FAMERP, São José do Rio Preto 15090-000, Brazil; (L.P.S.); (M.M.U.C.-N.); (P.M.B.-C.); (E.C.P.)
| | - Eny Maria Goloni-Bertollo
- Research Unit in Genetics and Molecular Biology—UPGEM, Faculty of Medicine of São José do Rio Preto—FAMERP, São José do Rio Preto 15090-000, Brazil; (L.P.S.); (M.M.U.C.-N.); (P.M.B.-C.); (E.C.P.)
- Correspondence: ; Tel.: +55-17-3201-5720
| |
Collapse
|
3
|
Sand M, Hessam S, Amur S, Skrygan M, Bromba M, Stockfleth E, Gambichler T, Bechara FG. Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. J Dermatol Sci 2017; 86:142-148. [PMID: 28187958 DOI: 10.1016/j.jdermsci.2017.01.012] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 10/05/2016] [Accepted: 01/30/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND A variety of cancers are associated with the expression of the oncogenic miR-17-92 cluster (Oncomir-1) and tumor suppressor miR-143-5p/miR-145-5p. Epidermal skin cancer has not been investigated for the expression of miR-17-92 and miR-143-145 clusters, despite being extensively studied regarding global microRNA profiles. The goal of this study was to investigate the expression and possible correlation of expression of miR17-92 and miR-143-145 cluster members in epidermal skin cancer. METHODS We evaluated punch biopsies from patients with cutaneous squamous cell carcinoma (cSCC, n=15) and basal cell carcinoma (BCC, n=16), along with control specimens from non-lesional epidermal skin (n=16). Expression levels of the miR17-92 cluster (including miR-17-5p, miR-17-3p, miR-18a-3p, miR-18a-5p, miR-19a-3p, miR-19a-5p, miR-19b-3p, miR-19b-1-5p, miR-20a-3p, miR-20a-5p, miR-92a-3p, and miR-92a-5p) and the tumor-suppressive cluster miR-143-145 (including miR-143-5p and miR-145-5p) were detected by quantitative real-time reverse transcriptase polymerase chain reaction. RESULTS We noted a highly significant increased expression of the miR-17-92 members miR-17-5p, miR-18a-5p, miR19a-3p, and miR-19b-3p and tumor suppressor miR-143-5p (p<0.01) in cSCC. miR-145-5p had a significantly decreased expression (p<0.05) for in BCC. A correlation analysis revealed multiple correlating miRNA-pairs within and between the investigated clusters. CONCLUSION This study marks the first evidence for the participation of members of the miR-17-92 cluster in cSCC and miR-143-145 cluster in BCC.
Collapse
Affiliation(s)
- Michael Sand
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany; Department of Plastic Surgery, St. Josef Hospital, Catholic Clinics of the Ruhr Peninsula, 45257 Essen, Germany.
| | - Schapoor Hessam
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
| | - Susanne Amur
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany; Department of Plastic Surgery, St. Josef Hospital, Catholic Clinics of the Ruhr Peninsula, 45257 Essen, Germany
| | - Marina Skrygan
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
| | - Michael Bromba
- Department of Plastic Surgery, St. Josef Hospital, Catholic Clinics of the Ruhr Peninsula, 45257 Essen, Germany
| | - Eggert Stockfleth
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
| | - Thilo Gambichler
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
| | - Falk G Bechara
- Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
| |
Collapse
|
4
|
Venza M, Visalli M, Beninati C, Benfatto S, Teti D, Venza I. miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. Int Immunopharmacol 2016; 40:235-243. [PMID: 27620505 DOI: 10.1016/j.intimp.2016.09.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 09/01/2016] [Accepted: 09/02/2016] [Indexed: 12/23/2022]
Abstract
Increasing evidence has demonstrated that in several tumors c-myc acts either as an oncogène or as a proapoptotic agent, depending on binding partner interactions. Recently, we showed that up-regulation of this gene by the histone deacetylase inhibitor MS-275 was responsible for sensitization to TRAIL-induced apoptosis through c-FLIP repression in melanoma. The present study aimed at investigating whether, in addition to inducing H3 hyperacetylation at the c-myc promoter, MS-275 could enhance cell death through the regulation of miRNAs involved in apoptosis, such as the miR-17-92 cluster. Following MS-275 treatment, a decrease in miR-92a-3p was observed either in TRAIL-resistant or TRAIL-sensitive cutaneous and uveal melanoma cells. Prediction tools revealed that miR-92a-3p targeted MYCBP2. Gain- and loss-of-function experiments showed that the 3'-UTR of MYCBP2 mRNA was the target of miR-92a-3p, as ectopic expression of miR-92a-3p resulted in MYCBP2 downregulation whereas miR-92a-3p knockdown markedly increased the expression of MYCBP2. Silencing of MYCBP2 counteracted the pro-apoptotic effects exerted by the down-regulation of miR-92a-3p and prevented c-myc-induced repression of c-FLIP, indicating a pivotal role of MYCBP2 as a mediator of miR-92a-3p and c-myc function. Together, our findings indicate that the MS-275-triggered downregulation of the oncogenic miR-92a-3p- which leads to the overexpression of its target gene MYCBP2 - is an event required for the enhanced susceptibility of melanoma cells to TRAIL-mediated apoptosis. Our data illustrate another epigenetic mechanism activated by MS-275 at the post-transcriptional level in melanoma, in addition to its best-known effects at the transcriptional level.
Collapse
Affiliation(s)
- Mario Venza
- Department of Biomedical Sciences and of Morphological and Functional Images, University of Messina, Messina, Italy
| | - Maria Visalli
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - Concetta Beninati
- Department of Human Pathology of Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy; Scylla Biotech Srl, University of Messina, Messina, Italy
| | - Salvatore Benfatto
- Department of Human Pathology of Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy
| | - Diana Teti
- Charybdis Vaccines Srl, University of Messina, Messina, Italy
| | - Isabella Venza
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
| |
Collapse
|
5
|
Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G. miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget 2016; 6:19006-16. [PMID: 26158900 PMCID: PMC4662471 DOI: 10.18632/oncotarget.4147] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 05/20/2015] [Indexed: 12/18/2022] Open
Abstract
Melanoma is an aggressive malignancy with a high metastatic potential. microRNA-17 (miR-17) is a member of the oncogenic miR-17/92 cluster. Here we study the effect of miR-17 on melanoma cell motility. Over expression of the mature or pri-microRNA form of miR-17 in WM-266-4 and 624mel melanoma lines enhances cell motility, evident in both wound healing and transwell migration assays. TargetScan algorithm predicts the PEA3-subfamily member ETV1 as a direct target of miR-17. Indeed, a 3–4-fold decrease of ETV1 protein levels are observed following miR-17 transfection into the various melanoma lines, with no significant change in ETV1 mRNA expression. Dual luciferase experiments demonstrate direct binding of miR-17 to the 3′-untranslated region of ETV1, confirmed by abolishing point mutations in the putative binding site. These combined results suggest regulation of ETV1 by miR-17 by a direct translational repression. Further, in both melanoma cell lines ETV1 knockdown by selective siRNA successfully pheno-copies the facilitated cell migration, while overexpression of ETV1 inhibits cell motility and migration. Altered ETV1 expression does not affect melanoma net-proliferation. In conclusion, we show a new role for miR-17 in melanoma, facilitating cell motility, by targeting the translation of ETV1 protein, which may support the development of metastasis.
Collapse
Affiliation(s)
- Ronit Cohen
- Ella Institute of Melanoma Research, Sheba Medical Center, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eyal Greenberg
- Ella Institute of Melanoma Research, Sheba Medical Center, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Yael Nemlich
- Ella Institute of Melanoma Research, Sheba Medical Center, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Jacob Schachter
- Ella Institute of Melanoma Research, Sheba Medical Center, Ramat-Gan, Israel
| | - Gal Markel
- Ella Institute of Melanoma Research, Sheba Medical Center, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel
| |
Collapse
|
6
|
Mione M, Bosserhoff A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res 2015; 28:340-54. [PMID: 25515738 DOI: 10.1111/pcmr.12346] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 12/15/2014] [Indexed: 12/18/2022]
Abstract
The importance of microRNAs as key molecular components of cellular processes is now being recognized. Recent reports have shown that microRNAs regulate processes as diverse as protein expression and nuclear functions inside cells and are able to signal extracellularly, delivered via exosomes, to influence cell fate at a distance. The versatility of microRNAs as molecular tools inspires the design of novel strategies to control gene expression, protein stability, DNA repair and chromatin accessibility that may prove very useful for therapeutic approaches due to the extensive manageability of these small molecules. However, we still lack a comprehensive understanding of the microRNA network and its interactions with the other layers of regulatory elements in cellular and extracellular functions. This knowledge may be necessary before we exploit microRNA versatility in therapeutic settings. To identify rules of interactions between microRNAs and other regulatory systems, we begin by reviewing microRNA activities in a single cell type: the melanocyte, from development to disease.
Collapse
Affiliation(s)
- Marina Mione
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggestein-Leopoldshafen, Germany
| | | |
Collapse
|
7
|
Shen Z, Wu X, Wang Z, Li B, Zhu X. Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:643-648. [PMID: 25755757 PMCID: PMC4348909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Accepted: 12/01/2014] [Indexed: 06/04/2023]
Abstract
The aim of the present study is to investigate whether there is a relationship between miR-18a expression and radiosensitization of non-small-cell lung caner (NSCLC). The relationship between miR-18a expression and clinicopathological characteristics was investigated. To determine whether the miR-18a expression levels were associated with radiotherapeutic efficacy, therapeutic response was evaluated by radiologic Response Evaluation Criteria in Solid Tumors (RECIST). To determine whether miR-18a was required for lung cancer cell radioresistance, A549 cells were treated with different doses of ionizing radiation, following transfection with inhibitor miR-18a or inhibitor NC. We found that the level of miR-18a in NSCLC was strongly correlated with tumor differentiation (P = 0.026), regional lymph node metastasis (P = 0.013) and clinical TNM stage (P = 0.005). According to RECIST, miR-18a expression level was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients. Furthermore, the depletion of miR-18a increased A549 cell radiosensitivity. In conclusion, we provide the evidence that down-regulation of miR-18a sensitizes NSCLC to radiation treatment, and it may help to develop a new approach to sensitizing radioresistant lung cancer cells by targeting miR-18a.
Collapse
Affiliation(s)
- Zetian Shen
- Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing UniversityNanjing 210002, Jiangsu Province, China
| | - Xinhu Wu
- Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing UniversityNanjing 210002, Jiangsu Province, China
| | - Zhen Wang
- Department of Hyperbaric Oxygen, Jinling Hospital, Medical School of Nanjing UniversityNanjing 210002, Jiangsu Province, China
| | - Bing Li
- Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing UniversityNanjing 210002, Jiangsu Province, China
| | - Xixu Zhu
- Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing UniversityNanjing 210002, Jiangsu Province, China
| |
Collapse
|
8
|
Zhang R, Wang W, Li F, Zhang H, Liu J. MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. Med Oncol 2014; 31:243. [PMID: 25218271 DOI: 10.1007/s12032-014-0243-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Accepted: 09/10/2014] [Indexed: 02/07/2023]
Abstract
MiR-106b~25 has been researched in several cancers. The aim of this study was to test miR-106b~25 expressions in 40 operative specimens and 20 pre-operative plasma samples of GC patients and explore the correlations between these miRNAs and some related clinical pathological factors. Compared with corresponding adjacent non-tumorous tissues, the expression of miR-106b~25 cluster increased significantly in gastric cancer tissues from 40 samples, with a median relative expression of 2.41(miR-106b), 2.83(miR-93) and 2.71(miR-25). The expression of miRNA-106b~25 cluster in tumor tissues was significantly correlated with tumor size, borrmann type, depth of tumor invasion (T), lymph node metastases (N), distant metastasis (M) and TNM stage (P<0.05). The expressive level of miRNA-106b~25 cluster was also statistically significant higher than healthy volunteers in plasma, with a median of 2.51(miR-106b), 2.32(miR-93) and 2.10(miR-25). The expression of miR-106b~25 cluster in plasma was significantly correlated with tumor size, borrmann type and TNM stage (P<0.05) in GC patients. What's more, the three components of miR-106b~25 cluster expressed consistently at a high level both in specimens and plasma. Considering the relationship between three miRNAs and some clinical pathological factors (TNM stage), it was implied that miR-106b~25 could be the next potential tumor biomarker for diagnosis and predictive prognosis for gastric cancer patients.
Collapse
Affiliation(s)
- Rupeng Zhang
- Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
| | | | | | | | | |
Collapse
|